Focus on Serotonin Uptake Inhibitor Research (Nova Biomedical)

The most significant class of antidepressants marketed in recent years is the selective serotonin re-uptake inhibitors (SSRIs). Claims of decreased adverse effects (ADRs) and increased safety have led to extensive use of these drugs by non-psychiatrists. The six SSRIs available in the United States are citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft). The primary uses for the SSRIs include unipolar and bipolar major depression and all of the anxiety disorders. However, controlled trials also support the use of SSRIs in the treatment of other psychiatric disorders including dysthymia, pre-menstrual dysphoria, bulimia nervosa, obesity, borderline personality disorder, alcoholism, rheumatic pain, and migraine headache. This new book presents leading-edge research from throughout the world on this topic.